[go: up one dir, main page]

BRPI0819295A2 - Sistema para liberação em uma célula xcr1 positiva e usos do mesmo - Google Patents

Sistema para liberação em uma célula xcr1 positiva e usos do mesmo

Info

Publication number
BRPI0819295A2
BRPI0819295A2 BRPI0819295A BRPI0819295A2 BR PI0819295 A2 BRPI0819295 A2 BR PI0819295A2 BR PI0819295 A BRPI0819295 A BR PI0819295A BR PI0819295 A2 BRPI0819295 A2 BR PI0819295A2
Authority
BR
Brazil
Prior art keywords
xcr1
releasing
positive
cell
xcr1 cell
Prior art date
Application number
Other languages
English (en)
Inventor
Richard Kroczek
Original Assignee
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Präsiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Präsiden filed Critical Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Präsiden
Publication of BRPI0819295A2 publication Critical patent/BRPI0819295A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6056Antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BRPI0819295 2007-11-20 2008-11-19 Sistema para liberação em uma célula xcr1 positiva e usos do mesmo BRPI0819295A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07022471A EP2062592A1 (en) 2007-11-20 2007-11-20 System for delivery into a XCR1 positive cell and uses thereof
US1326307P 2007-12-12 2007-12-12
PCT/EP2008/009758 WO2009065561A2 (en) 2007-11-20 2008-11-19 System for delivery into a xcr1 positive cell and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0819295A2 true BRPI0819295A2 (pt) 2015-05-05

Family

ID=39267731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819295 BRPI0819295A2 (pt) 2007-11-20 2008-11-19 Sistema para liberação em uma célula xcr1 positiva e usos do mesmo

Country Status (9)

Country Link
US (1) US10703817B2 (pt)
EP (2) EP2062592A1 (pt)
JP (2) JP2011503219A (pt)
CN (1) CN101896191B (pt)
AU (1) AU2008328183B2 (pt)
BR (1) BRPI0819295A2 (pt)
CA (1) CA2705588A1 (pt)
MX (1) MX2010005451A (pt)
WO (1) WO2009065561A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
HK1199038A1 (en) * 2011-09-01 2015-06-19 卫材研发管理有限公司 Anti-human xcr1 antibodies
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US20130245236A1 (en) * 2012-03-15 2013-09-19 Richard Kroczek Antibodies to the chemokine receptor xcr1
CA2942610C (en) * 2014-03-17 2024-02-20 Richard Kroczek Use of a medicament comprising a peptide-loaded peripheral blood mononuclear cell for extending a cellular cytotoxic immune response
WO2015157652A1 (en) 2014-04-11 2015-10-15 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
EP3186282A1 (en) * 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
KR101833971B1 (ko) * 2016-02-19 2018-03-02 사회복지법인 삼성생명공익재단 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물
CN105622762B (zh) * 2016-03-03 2020-04-03 中国农业科学院兰州兽医研究所 一种牛趋化因子介导的o型口蹄疫靶向性复合表位蛋白及疫苗
CN105777909B (zh) * 2016-03-03 2020-04-03 中国农业科学院兰州兽医研究所 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗
CN107056932B (zh) * 2016-12-24 2021-04-09 深圳大学 一种氨基酸序列、含ova表位的融合蛋白及其制备方法和应用
WO2018187590A1 (en) * 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US10815520B2 (en) 2017-04-07 2020-10-27 University Of Louisville Research Foundation, Inc. Nanovesicles, methods, and systems for diagnosis and prognosis of cancer
US12036262B2 (en) 2017-11-22 2024-07-16 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
JP2021529535A (ja) * 2018-07-02 2021-11-04 ピュアテック エルワイティー, インコーポレイテッド 生物学的薬剤の送達に使用する乳小胞
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
WO2020127277A1 (en) 2018-12-18 2020-06-25 Robert Koch-Institut A peptide-loaded mhc-i presenting cell and an il-2 with extended half-life for amplifying a cellular cytotoxic immune response
JP7677892B2 (ja) 2018-12-28 2025-05-15 エフ. ホフマン-ラ ロシュ アーゲー 免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶
CN115551537A (zh) 2019-12-03 2022-12-30 纽沃进公司 肿瘤细胞疫苗
CN113072646A (zh) * 2021-06-04 2021-07-06 北京承诺未来科技有限公司 靶向egfr的肿瘤核酸疫苗
CN113072647B (zh) * 2021-06-04 2021-08-13 诺未科技(北京)有限公司 靶向人乳头瘤病毒的核酸疫苗
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN119894525A (zh) * 2022-07-15 2025-04-25 哈佛大学校长及研究员协会 Mucispirillum组合物及其癌症治疗方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5780268A (en) * 1995-12-06 1998-07-14 Incyte Pharmaceuticals Chemokine expressed in a mixed lymphocyte reaction
US6395268B1 (en) * 1996-10-24 2002-05-28 Schering Corporation Lymphotactin uses
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
ES2205849T3 (es) * 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
JP4486257B2 (ja) 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
US20030124627A1 (en) * 2001-11-29 2003-07-03 Burmer Glenna C. Diagnostic and therapeutic compositions and methods related to chemokine (C motif ) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR)
KR100442963B1 (ko) * 2001-12-29 2004-08-04 주식회사 하이닉스반도체 고순도의 금속막 제조방법
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20050136033A9 (en) * 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
US20060257359A1 (en) * 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
EP1698902A1 (en) * 2005-03-01 2006-09-06 DKFZ Deutsches Krebsforschungszentrum Use of XCR1 for diagnosing or monitoring of immune tolerance

Also Published As

Publication number Publication date
CN101896191B (zh) 2017-08-25
JP2011503219A (ja) 2011-01-27
WO2009065561A3 (en) 2009-09-03
US20100310562A1 (en) 2010-12-09
EP2200633B1 (en) 2018-05-23
JP5946494B2 (ja) 2016-07-06
US10703817B2 (en) 2020-07-07
CA2705588A1 (en) 2009-05-28
MX2010005451A (es) 2010-08-09
AU2008328183B2 (en) 2013-12-12
CN101896191A (zh) 2010-11-24
EP2062592A1 (en) 2009-05-27
EP2200633A2 (en) 2010-06-30
WO2009065561A8 (en) 2010-06-10
JP2015007052A (ja) 2015-01-15
AU2008328183A1 (en) 2009-05-28
WO2009065561A2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
BRPI0819295A2 (pt) Sistema para liberação em uma célula xcr1 positiva e usos do mesmo
BR112012009921A2 (pt) métodos para reprogramar células e usos do mesmos
BRPI1011725A2 (pt) método e sistema para direcionar uma resposta biológica localizada em um implante
BRPI0908983A2 (pt) sistema e dispositvo de célula de combustível
BRPI1006922A2 (pt) sistema para descarte de medicação
EP2109913A4 (en) ELECTROCHEMICAL CELL SYSTEM
BRPI1012304A2 (pt) sistema para auxílio de subida
BRPI0817335A2 (pt) método e sistema para desviar uma célula de energia de um suprimento de energia
BRPI0810097A2 (pt) Sistemas e métodos para separação de líquidos
BRPI0813429A2 (pt) sistema e método para uma mbms aperfeiçoada para uma transferência de pss
BRPI1009314A2 (pt) sistema e método para armazenar e liberar energia
BRPI1006542A2 (pt) sistema e método para detectar uma queda de um usuário
BR112013008410A2 (pt) sistema para uso em reparação tecidual
BRPI0817299A2 (pt) Vacinas e componentes de vacina para inibição de células microbianas
BRPI0820253A2 (pt) Sistema de sensoriamento, e, método para sensoriar uma mudança em uma propriedade de um material
BRPI0819117A2 (pt) sistema de dispensação de composição de combustível, e, método para fornecer uma composição de combustível
BRPI0908003A2 (pt) sistemas e métodos para o envio de terapia de radiação
BRPI0924310A2 (pt) sistema e método de gestao e arquivo de conteúdos escolares
DE112008000870B8 (de) Brennstoffzellensystem
BR112012003233A2 (pt) sistema e reservatório de segurança para alimentação enteral
DE112008000649B8 (de) Brennstoffzellensystem
BRPI1007681A2 (pt) sistema de para ventos
BRPI0818858A2 (pt) Sistema de atracamento e de ancoragem automatizado
BRPI0817505A2 (pt) Sistema e método para replicação e sincronismo
BRPI0821617A2 (pt) Dispositivos e métodos para reatores de fluxo contínuo alveolados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 38/19 (2006.01), A61K 3

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06T Formal requirements before examination
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL